Symbols / SLS $4.13 -1.90% SELLAS Life Sciences Group, Inc.
SLS Chart
About
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 741.68M |
| Enterprise Value | 670.88M | Income | -26.86M | Sales | — |
| Book/sh | 0.46 | Cash/sh | 0.40 | Dividend Yield | — |
| Payout | 0.00% | Employees | 13 | IPO | — |
| P/E | — | Forward P/E | -22.94 | PEG | — |
| P/S | — | P/B | 8.92 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 10.23 |
| Current Ratio | 10.72 | Debt/Eq | 1.41 | LT Debt/Eq | — |
| EPS (ttm) | -0.25 | EPS next Y | -0.18 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-12 | ROA | -34.74% |
| ROE | -66.88% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 179.58M |
| Shs Float | 178.82M | Short Float | 25.66% | Short Ratio | 6.54 |
| Short Interest | — | 52W High | 6.14 | 52W Low | 0.95 |
| Beta | 2.23 | Avg Volume | 7.56M | Volume | 4.87M |
| Target Price | $8.67 | Recom | Strong_buy | Prev Close | $4.21 |
| Price | $4.13 | Change | -1.90% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.67
Mean price target
2. Current target
$4.13
Latest analyst target
3. DCF / Fair value
$-1.85
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.13
Low
$6.00
High
$10.00
Mean
$8.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-12 | main | Maxim Group | Buy → Buy | $10 |
| 2025-07-16 | main | Maxim Group | Buy → Buy | $7 |
| 2023-11-22 | reit | Cantor Fitzgerald | Overweight → Overweight | $3 |
| 2023-09-07 | reit | Cantor Fitzgerald | Overweight → Overweight | $3 |
| 2022-11-15 | main | Alliance Global Partners | — → Buy | $8 |
| 2022-06-28 | main | Cantor Fitzgerald | — → Overweight | $6 |
| 2021-07-21 | init | Cantor Fitzgerald | — → Overweight | $18 |
| 2019-11-15 | up | Maxim Group | Hold → Buy | $12 |
| 2019-04-08 | init | Alliance Global Partners | — → Buy | $5 |
| 2018-11-01 | init | Oppenheimer | — → Outperform | $13 |
| 2018-07-20 | main | Maxim Group | Buy → Buy | $5 |
| 2018-04-02 | init | HC Wainwright & Co. | — → Buy | $11 |
| 2018-03-19 | up | Maxim Group | Hold → Buy | — |
News
RSS: Latest SLS news- Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15% - MSN Fri, 03 Apr 2026 16
- SLS Stock Price, Quote & Chart | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - chartmill.com hu, 02 Apr 2026 07
- SLS Stock In Focus As Alliance Global Sees 92% Upside Following AML Trial Updates - Stocktwits Fri, 20 Mar 2026 15
- Why SELLAS Life Sciences Group (SLS) Is Down 8.3% After US$150 Million ATM Offering News - simplywall.st Mon, 30 Mar 2026 03
- SELLAS nears key leukemia trial readout after raising $42.6M in Q1 - Stock Titan hu, 19 Mar 2026 07
- SLS stock jumps after Merck's Tern deal sparks buyout buzz in blood-cancer space: Retail bets on this big pharma suitor - MSN Wed, 01 Apr 2026 07
- SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 7.7% - Here's Why - MarketBeat Mon, 30 Mar 2026 20
- $SLS stock is down 9% today. Here's what we see in our data. - Quiver Quantitative Mon, 30 Mar 2026 19
- SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths - finance.yahoo.com Fri, 20 Mar 2026 07
- SELLAS LIFE SCIENCES GROUP I (SLS) Fundamental Analysis & Valuation - chartmill.com hu, 02 Apr 2026 07
- SLS Stock Jumps After Merck's Tern Deal Sparks Buyout Buzz In Blood-Cancer Space: Retail Bets On This Big Pharma Suitor - Stocktwits Wed, 25 Mar 2026 07
- AI-guided leukemia trial enrolls those unlikely to benefit from aza/ven therapy - Stock Titan hu, 12 Mar 2026 07
- SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum - Stocktwits Wed, 18 Mar 2026 07
- SELLAS (NASDAQ: SLS) registers shelf and $150M ATM with TD Cowen - Stock Titan Fri, 20 Mar 2026 07
- SLS stock rallies ahead of AML trial readout — 'Pharma Bro' Martin Shkreli says he's still 'very bearish,' predicts drug will fail - MSN Fri, 03 Apr 2026 13
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
-100.00%
|
1.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
-100.00%
|
1.00
|
| Cost Of Revenue |
|
—
|
—
|
0.00
-100.00%
|
0.10
|
| Reconciled Cost Of Revenue |
|
—
|
—
|
0.00
-100.00%
|
0.10
|
| Gross Profit |
|
—
|
—
|
0.00
-100.00%
|
0.90
|
| Operating Expense |
|
28.27
-10.28%
|
31.51
-16.78%
|
37.87
+15.28%
|
32.85
|
| Research And Development |
|
16.02
-16.10%
|
19.10
-20.46%
|
24.01
+18.45%
|
20.27
|
| Selling General And Administration |
|
12.25
-1.33%
|
12.42
-10.42%
|
13.86
+10.17%
|
12.58
|
| General And Administrative Expense |
|
12.25
-1.33%
|
12.42
-10.42%
|
13.86
+10.17%
|
12.58
|
| Other Gand A |
|
12.25
-1.33%
|
12.42
-10.42%
|
13.86
+10.17%
|
12.58
|
| Total Expenses |
|
28.27
-10.28%
|
31.51
-16.78%
|
37.87
+14.93%
|
32.95
|
| Operating Income |
|
-28.27
+10.28%
|
-31.51
+16.78%
|
-37.87
-18.53%
|
-31.95
|
| Total Operating Income As Reported |
|
-28.27
+10.28%
|
-31.51
+16.78%
|
-37.87
+9.73%
|
-41.95
|
| EBITDA |
|
-28.27
+10.28%
|
-31.51
+16.78%
|
-37.87
-18.53%
|
-31.95
|
| Normalized EBITDA |
|
-28.27
+10.28%
|
-31.51
+16.79%
|
-37.87
-69.97%
|
-22.28
|
| EBIT |
|
-28.27
+10.28%
|
-31.51
+16.78%
|
-37.87
-18.53%
|
-31.95
|
| Total Unusual Items |
|
—
|
—
|
0.00
+100.04%
|
-9.67
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
0.00
+100.04%
|
-9.67
|
| Special Income Charges |
|
—
|
—
|
0.00
+100.00%
|
-9.70
|
| Other Special Charges |
|
—
|
—
|
—
|
10.00
|
| Impairment Of Capital Assets |
|
—
|
—
|
—
|
0.00
|
| Restructuring And Mergern Acquisition |
|
—
|
—
|
0.00
+100.00%
|
-0.30
|
| Net Income |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Pretax Income |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Net Non Operating Interest Income Expense |
|
1.41
+123.26%
|
0.63
+20.38%
|
0.53
+65.62%
|
0.32
|
| Net Interest Income |
|
1.41
+123.26%
|
0.63
+20.38%
|
0.53
+65.62%
|
0.32
|
| Interest Income Non Operating |
|
1.41
+123.26%
|
0.63
+20.38%
|
0.53
+65.62%
|
0.32
|
| Interest Income |
|
1.41
+123.26%
|
0.63
+20.38%
|
0.53
+65.62%
|
0.32
|
| Other Income Expense |
|
—
|
—
|
0.00
+100.04%
|
-9.67
|
| Gain On Sale Of Security |
|
—
|
—
|
0.00
-88.89%
|
0.04
|
| Tax Provision |
|
—
|
—
|
—
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Net Income From Continuing Operation Net Minority Interest |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Net Income From Continuing And Discontinued Operation |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Net Income Continuous Operations |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Normalized Income |
|
-26.86
+13.01%
|
-30.88
+17.31%
|
-37.34
-18.05%
|
-31.63
|
| Net Income Common Stockholders |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
—
|
| Diluted EPS |
|
-0.25
+50.00%
|
-0.50
+62.69%
|
-1.34
+37.09%
|
-2.13
|
| Basic EPS |
|
-0.25
+50.00%
|
-0.50
+62.69%
|
-1.34
+37.09%
|
-2.13
|
| Basic Average Shares |
|
109.05
+78.18%
|
61.20
+120.33%
|
27.78
+43.21%
|
19.40
|
| Diluted Average Shares |
|
109.05
+78.18%
|
61.20
+120.33%
|
27.78
+43.21%
|
19.40
|
| Diluted NI Availto Com Stockholders |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
78.34
+303.18%
|
19.43
+212.46%
|
6.22
-70.31%
|
20.94
|
| Current Assets |
|
75.21
+360.65%
|
16.33
+414.72%
|
3.17
-82.14%
|
17.76
|
| Cash Cash Equivalents And Short Term Investments |
|
71.79
+417.02%
|
13.89
+448.85%
|
2.53
-85.23%
|
17.12
|
| Cash And Cash Equivalents |
|
71.79
+417.02%
|
13.89
+448.85%
|
2.53
-85.23%
|
17.12
|
| Receivables |
|
—
|
—
|
—
|
—
|
| Prepaid Assets |
|
3.10
+32.21%
|
2.34
+331.92%
|
0.54
+11.75%
|
0.48
|
| Restricted Cash |
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
|
| Other Current Assets |
|
0.22
|
—
|
—
|
0.05
|
| Total Non Current Assets |
|
3.13
+0.93%
|
3.10
+1.90%
|
3.05
-4.39%
|
3.19
|
| Net PPE |
|
0.96
+4.11%
|
0.93
+7.81%
|
0.86
-1.83%
|
0.87
|
| Gross PPE |
|
0.96
+4.11%
|
0.93
+7.81%
|
0.86
-1.83%
|
0.87
|
| Other Properties |
|
0.96
+4.11%
|
0.93
+7.81%
|
0.86
-1.83%
|
0.87
|
| Goodwill And Other Intangible Assets |
|
1.91
+0.00%
|
1.91
+0.00%
|
1.91
+0.00%
|
1.91
|
| Goodwill |
|
1.91
+0.00%
|
1.91
+0.00%
|
1.91
+0.00%
|
1.91
|
| Non Current Prepaid Assets |
|
—
|
—
|
—
|
0.40
|
| Other Non Current Assets |
|
0.26
-3.38%
|
0.27
-3.27%
|
0.28
-31.08%
|
0.40
|
| Total Liabilities Net Minority Interest |
|
7.47
-25.01%
|
9.97
-29.79%
|
14.20
-11.79%
|
16.09
|
| Current Liabilities |
|
7.02
-26.21%
|
9.51
-30.76%
|
13.73
-11.47%
|
15.52
|
| Payables And Accrued Expenses |
|
4.68
-34.55%
|
7.15
-39.20%
|
11.75
-14.23%
|
13.70
|
| Payables |
|
2.95
-15.77%
|
3.50
-37.93%
|
5.64
-36.33%
|
8.86
|
| Accounts Payable |
|
2.95
-15.77%
|
3.50
-37.93%
|
5.64
+67.98%
|
3.36
|
| Other Payable |
|
—
|
—
|
—
|
5.50
|
| Current Accrued Expenses |
|
1.73
-52.56%
|
3.65
-40.36%
|
6.12
+26.16%
|
4.85
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.75
-1.35%
|
1.78
+19.02%
|
1.49
+3.75%
|
1.44
|
| Current Debt And Capital Lease Obligation |
|
0.54
+0.00%
|
0.54
+21.97%
|
0.45
+19.89%
|
0.37
|
| Current Capital Lease Obligation |
|
0.54
+0.00%
|
0.54
+21.97%
|
0.45
+19.89%
|
0.37
|
| Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Current Deferred Revenue |
|
—
|
—
|
—
|
—
|
| Other Current Liabilities |
|
0.04
+0.00%
|
0.04
+0.00%
|
0.04
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.46
+0.00%
|
0.46
-0.65%
|
0.46
-20.28%
|
0.58
|
| Long Term Debt And Capital Lease Obligation |
|
0.46
+0.00%
|
0.46
-0.65%
|
0.46
-19.72%
|
0.57
|
| Long Term Capital Lease Obligation |
|
0.46
+0.00%
|
0.46
-0.65%
|
0.46
-19.72%
|
0.57
|
| Non Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
—
|
—
|
—
|
—
|
| Other Non Current Liabilities |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
70.87
+648.77%
|
9.46
+218.67%
|
-7.98
-264.42%
|
4.85
|
| Common Stock Equity |
|
70.87
+648.77%
|
9.46
+218.67%
|
-7.98
-264.42%
|
4.85
|
| Capital Stock |
|
0.01
+114.29%
|
0.01
+133.33%
|
0.00
+50.00%
|
0.00
|
| Common Stock |
|
0.01
+114.29%
|
0.01
+133.33%
|
0.00
+50.00%
|
0.00
|
| Preferred Stock |
|
—
|
—
|
0.00
|
0.00
|
| Share Issued |
|
153.10
+106.96%
|
73.98
+130.22%
|
32.13
+52.97%
|
21.01
|
| Ordinary Shares Number |
|
153.10
+106.96%
|
73.98
+130.22%
|
32.13
+52.97%
|
21.01
|
| Additional Paid In Capital |
|
345.84
+34.27%
|
257.58
+23.09%
|
209.26
+13.27%
|
184.75
|
| Retained Earnings |
|
-274.99
-10.83%
|
-248.12
-14.21%
|
-217.24
-20.76%
|
-179.90
|
| Total Equity Gross Minority Interest |
|
70.87
+648.77%
|
9.46
+218.67%
|
-7.98
-264.42%
|
4.85
|
| Total Capitalization |
|
70.87
+648.77%
|
9.46
+218.67%
|
-7.98
-264.42%
|
4.85
|
| Working Capital |
|
68.19
+900.35%
|
6.82
+164.54%
|
-10.56
-571.35%
|
2.24
|
| Invested Capital |
|
70.87
+648.77%
|
9.46
+218.67%
|
-7.98
-264.42%
|
4.85
|
| Total Debt |
|
1.00
+0.00%
|
1.00
+10.49%
|
0.91
-4.13%
|
0.94
|
| Capital Lease Obligations |
|
1.00
+0.00%
|
1.00
+10.49%
|
0.91
-4.13%
|
0.94
|
| Net Tangible Assets |
|
68.96
+813.22%
|
7.55
+176.35%
|
-9.89
-436.74%
|
2.94
|
| Tangible Book Value |
|
68.96
+813.22%
|
7.55
+176.35%
|
-9.89
-436.74%
|
2.94
|
| Derivative Product Liabilities |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-28.39
+19.81%
|
-35.40
-12.71%
|
-31.41
-31.92%
|
-23.81
|
| Cash Flow From Continuing Operating Activities |
|
-28.39
+19.81%
|
-35.40
-12.71%
|
-31.41
-31.92%
|
-23.81
|
| Net Income From Continuing Operations |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Other Non Cash Items |
|
0.60
+6.42%
|
0.56
+13.33%
|
0.49
-95.13%
|
10.16
|
| Stock Based Compensation |
|
1.96
+25.06%
|
1.56
-25.31%
|
2.09
+21.32%
|
1.73
|
| Asset Impairment Charge |
|
—
|
—
|
—
|
0.00
|
| Deferred Tax |
|
—
|
—
|
—
|
0.00
|
| Deferred Income Tax |
|
—
|
—
|
—
|
0.00
|
| Operating Gains Losses |
|
—
|
—
|
-0.00
+88.89%
|
-0.04
|
| Gain Loss On Investment Securities |
|
—
|
—
|
-0.00
+88.89%
|
-0.04
|
| Change In Working Capital |
|
-4.08
+38.62%
|
-6.65
-298.68%
|
3.35
-40.70%
|
5.64
|
| Change In Receivables |
|
—
|
—
|
—
|
0.00
|
| Change In Prepaid Assets |
|
-0.97
+45.92%
|
-1.79
-1684.07%
|
0.11
-90.98%
|
1.25
|
| Change In Payables And Accrued Expense |
|
-2.48
+42.72%
|
-4.32
-215.28%
|
3.75
-22.82%
|
4.86
|
| Change In Accrued Expense |
|
-1.94
+11.13%
|
-2.18
-250.72%
|
1.45
-60.26%
|
3.65
|
| Change In Payable |
|
-0.54
+74.99%
|
-2.14
-192.96%
|
2.30
+89.69%
|
1.21
|
| Change In Account Payable |
|
-0.54
+74.99%
|
-2.14
-192.96%
|
2.30
+89.69%
|
1.21
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
—
|
| Change In Other Current Liabilities |
|
-0.64
-19.14%
|
-0.53
-2.90%
|
-0.52
-9.98%
|
-0.47
|
| Investing Cash Flow |
|
—
|
0.00
+100.00%
|
-5.50
-22.22%
|
-4.50
|
| Cash Flow From Continuing Investing Activities |
|
—
|
0.00
+100.00%
|
-5.50
-22.22%
|
-4.50
|
| Capital Expenditure |
|
—
|
—
|
-5.50
-22.22%
|
-4.50
|
| Net Intangibles Purchase And Sale |
|
—
|
0.00
+100.00%
|
-5.50
-22.22%
|
-4.50
|
| Purchase Of Intangibles |
|
—
|
0.00
+100.00%
|
-5.50
-22.22%
|
-4.50
|
| Financing Cash Flow |
|
86.30
+84.56%
|
46.76
+109.54%
|
22.32
-7.33%
|
24.08
|
| Cash Flow From Continuing Financing Activities |
|
86.30
+84.56%
|
46.76
+109.54%
|
22.32
-7.33%
|
24.08
|
| Net Common Stock Issuance |
|
23.05
-50.07%
|
46.16
+107.71%
|
22.23
-7.37%
|
23.99
|
| Proceeds From Stock Option Exercised |
|
63.77
+9591.79%
|
0.66
+443.80%
|
0.12
+42.35%
|
0.09
|
| Net Other Financing Charges |
|
-0.53
-723.44%
|
-0.06
-106.45%
|
-0.03
|
—
|
| Changes In Cash |
|
57.91
+409.92%
|
11.36
+177.81%
|
-14.60
-245.04%
|
-4.23
|
| Beginning Cash Position |
|
13.99
+431.79%
|
2.63
-84.73%
|
17.23
-19.72%
|
21.45
|
| End Cash Position |
|
71.89
+414.04%
|
13.99
+431.79%
|
2.63
-84.73%
|
17.23
|
| Free Cash Flow |
|
-28.39
+19.81%
|
-35.40
+4.09%
|
-36.91
-30.38%
|
-28.31
|
| Common Stock Issuance |
|
23.05
-50.07%
|
46.16
+107.71%
|
22.23
-7.37%
|
23.99
|
| Issuance Of Capital Stock |
|
23.05
-50.07%
|
46.16
+107.71%
|
22.23
-7.37%
|
23.99
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-19 View
- 10-K2026-03-19 View
- 8-K2026-03-11 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 8-K2026-01-08 View
- 42025-12-05 View
- 42025-12-05 View
- 42025-12-05 View
- 42025-11-21 View
- 8-K2025-11-12 View
- 10-Q2025-11-12 View
- 8-K2025-10-27 View
- 8-K2025-10-03 View
- 8-K2025-09-11 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|